A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...
Morning Overview on MSN
Scientists uncover genetic switch that makes pancreatic cancer chemo-proof
Researchers at Duke-NUS Medical School have identified a molecular switch controlled by the protein GATA6 that determines whether pancreatic cancer cells respond to chemotherapy or become resistant.
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results